SPYRE THERAPEUTICS INC(SYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SYRE SPYRE THERAPEUTICS INC

盘后交易 09-24 16:18:01 EDT

87.09

-1.08

-1.22%

盘后87.09

+0.000.00%

16:15 EDT

最高87.46	最低82.93	成交量172.95万
今开87.46	昨收88.17	日振幅5.14%
总市值76.79亿	流通市值70.52亿	总股本8,817万
成交额1.47亿	换手率2.14%	流通股本8,098万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SYRE","market":"US","secType":"STK","nameCN":"SPYRE THERAPEUTICS INC","latestPrice":87.09,"timestamp":1790280000000,"preClose":88.17,"halted":0,"volume":1729484,"hourTrading":{"tag":"盘后","latestPrice":87.09,"preClose":87.09,"latestTime":"16:15 EDT","volume":18695,"amount":1628147.55,"timestamp":1790280900365,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.012249064307587595,"floatShares":80977000,"shares":88173800,"eps":-2.009956,"marketStatus":"盘后交易","change":-1.08,"latestTime":"09-24 16:18:01 EDT","open":87.46,"high":87.46,"low":82.93,"amount":147466903,"amplitude":0.051378,"askPrice":88.79,"askSize":22,"bidPrice":85.39,"bidSize":23,"shortable":3,"etf":0,"ttmEps":-2.009956,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1790294400000},"marketStatusCode":4,"adr":0,"listingDate":1460001600000,"exchange":"NASDAQ","adjPreClose":88.17,"preHourTrading":{"tag":"盘前","latestPrice":87.5,"preClose":88.17,"latestTime":"09:24 EDT","volume":14,"amount":1225,"timestamp":1790256281941,"change":-0.67,"changeRate":-0.007599,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":87.09,"preClose":87.09,"latestTime":"16:15 EDT","volume":18695,"amount":1628147.55,"timestamp":1790280900365,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.031057,"impliedVol":0.5942,"impliedVolPercentile":0.1076},"requestUrl":"/m/hq/s/SYRE","defaultTab":"news","newsList":[{"id":"1121233294","title":"Spyre Therapeutics旗下Spy003疗法在第12周实现20%临床缓解率及30%内镜改善率","url":"https://stock-news.laohu8.com/highlight/detail?id=1121233294","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121233294?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:03","pubTimestamp":1788868991,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics日前宣布，其研发管线中的关键候选药物Spy003在临床试验中交出了令人瞩目的阶段性答卷。数据显示，在接受治疗满12周的时间节点上，该疗法成功促成了20%的患者达到临床缓解状态，与此同时，30%的受试者在内镜检查中观察到了显著的病情改善迹象。这一成果不仅彰显了Spy003在疾病修饰层面的潜在威力，也为公司后续的注册性临床推进注入了强劲信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103784641","title":"Spyre Therapeutics盘前股价重挫12.4% 实验性药物未达类风湿关节炎单药治疗开发门槛","url":"https://stock-news.laohu8.com/highlight/detail?id=1103784641","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103784641?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:00","pubTimestamp":1787734809,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics股价在盘前交易时段大幅下跌12.4%，此前该公司宣布其一款实验性药物未能达到类风湿关节炎单药治疗开发所需的疗效阈值。这一消息令市场投资者颇感意外，引发对该生物科技公司研发管线前景的重新评估。受此利空冲击，该股在常规交易开始前即遭遇显著抛售压力，反映出市场对候选药物临床价值的疑虑正在加深。分析人士指出，未能跨越预设的疗效门槛意味着该药物作为单一疗法的开发路径将面临重大调整，公司或需重新考量其战略布局。投资者正密切关注公司后续的研发决策及可能的替代方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158063890","title":"Spyre Therapeutics公司——疗效幅度未达公司预设目标，类风湿关节炎候选药物SPY072单药疗法开发优先级或将调整","url":"https://stock-news.laohu8.com/highlight/detail?id=1158063890","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158063890?lang=zh_cn&edition=full","pubTime":"2026-08-26 04:02","pubTimestamp":1787688131,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics公司近日披露，其类风湿关节炎在研药物SPY072在临床试验中展现的疗效幅度未能达到公司预先设定的目标阈值。这一结果意味着，该公司此前规划的单药疗法开发路径——即将SPY072作为独立治疗方案推进的优先策略——如今面临重新审视与调整的现实压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107207144","title":"Spyre Therapeutics公司：Spy072联合Il17-a/F治疗化脓性汗腺炎（HS）预计于2027年末或2028年初启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1107207144","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107207144?lang=zh_cn&edition=full","pubTime":"2026-08-26 04:02","pubTimestamp":1787688130,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc宣布，其候选药物Spy072与Il17-a/F联合疗法用于治疗化脓性汗腺炎（HS）的计划，预计将在2027年末或2028年初推进。这一时间表标志着该公司在炎症性疾病领域管线布局的重要节点，也反映出其对该联合方案临床开发节奏的审慎把控。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LFSC","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157101849","title":"Spyre Therapeutics——Spy072在多项终点指标上较安慰剂展现统计学显著优势","url":"https://stock-news.laohu8.com/highlight/detail?id=1157101849","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157101849?lang=zh_cn&edition=full","pubTime":"2026-08-26 04:02","pubTimestamp":1787688129,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics宣布，其候选药物Spy072在多项临床试验终点上，相较于安慰剂组，取得了具有统计学意义的显著改善。这一积极结果标志着该药物在治疗潜力上迈出了坚实一步，为后续研发注入了强劲动力。尽管具体数据细节尚未完全披露，但公司方面对Spy072的前景表达了高度信心，并计划加速推进其临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103864507","title":"Spyre Therapeutics公布Spy072 Skyway二期试验类风湿关节炎亚研究顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1103864507","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103864507?lang=zh_cn&edition=full","pubTime":"2026-08-26 04:02","pubTimestamp":1787688128,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics今日宣布，其Spy072在Skyway二期试验中针对类风湿关节炎亚研究的顶线结果已正式揭晓。这一里程碑式的数据发布，为该公司在自身免疫性疾病领域的研发管线注入了新的看点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150250995","title":"Spyre Therapeutics推出Spy772项目，启动化脓性汗腺炎SkyLight二期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1150250995","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150250995?lang=zh_cn&edition=full","pubTime":"2026-08-10 20:01","pubTimestamp":1786363318,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics（股票代码：SYRE）正式宣布，其全新研发项目Spy772已启动，并同步开启针对化脓性汗腺炎（Hidradenitis Suppurativa）的SkyLight二期临床试验。这一消息标志着公司在炎症性疾病治疗领域迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177727349","title":"异动解读｜Spyre Therapeutics盘中上涨11.41%，报104.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177727349","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177727349?lang=zh_cn&edition=full","pubTime":"2026-07-15 00:01","pubTimestamp":1784044892,"startTime":"0","endTime":"0","summary":"7月15日，Spyre Therapeutics盘中上涨11.41%，报104.42美元/股，成交额7429.81万美元。Spyre Therapeutics所在的生物科技行业中，个股表现分化，其中Nextcure Inc.涨213.3%，渤健公司跌8.42%，艾伯维公司跌1.24%，Shuttle Pharmaceuticals Inc涨31.42%，吉利德科学跌0.49%。Spyre Therapeutics是一家临床阶段生物技术公司，致力于通过结合同类最佳的抗体工程、合理的治疗组合以及精准医疗方法，开发下一代炎症性肠病产品，管线涵盖针对α4β7、TL1A和IL-23的延长半衰期抗体。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193512223","title":"异动解读｜Spyre Therapeutics盘中上涨5.02%，报93.505美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193512223","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193512223?lang=zh_cn&edition=full","pubTime":"2026-07-08 00:15","pubTimestamp":1783440956,"startTime":"0","endTime":"0","summary":"7月8日，Spyre Therapeutics盘中上涨5.02%，报93.505美元/股，成交额3902.22万美元。Spyre Therapeutics所在的生物科技行业中，个股中，福泰制药跌1.11%，艾伯维公司涨0.99%，吉利德科学涨3.70%，Moderna跌3.34%，安进涨0.46%。Spyre Therapeutics是一家临床阶段生物技术公司，旨在通过结合同类最佳的抗体工程、合理的治疗组合以及精准医疗方法，创造下一代炎症性肠病产品，产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121929272","title":"异动解读｜SPYRE THERAPEUTICS盘前下跌5.04%，董事减持持续施压股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1121929272","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121929272?lang=zh_cn&edition=full","pubTime":"2026-06-25 16:18","pubTimestamp":1782375497,"startTime":"0","endTime":"0","summary":"6月25日，SPYRE THERAPEUTICS盘前下跌5.04%，报82.44美元/股，成交额1.8万美元。消息面上，公司董事Michael Thomas Henderson于6月22日出售2万股公司股票，总价值约200万美元，该消息于6月23日披露后持续发酵。此前交易日公司股价已大幅下挫逾13%，成交量超290万股，约为日均成交量的两倍以上。Spyre Therapeutics是一家专注于炎症性肠病的生物技术公司，产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143725534","title":"异动解读｜Spyre Therapeutics盘中下跌14.76%，董事减持引发市场关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1143725534","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143725534?lang=zh_cn&edition=full","pubTime":"2026-06-24 21:38","pubTimestamp":1782308280,"startTime":"0","endTime":"0","summary":"6月24日，Spyre Therapeutics盘中下跌14.76%，报85.19美元/股，成交额3673.81万美元。消息面上，公司于6月23日披露内部交易情况，董事HENDERSON MICHAEL THOMAS于6月22日卖出2万股公司股票。对于一家尚处于亏损阶段、市盈率为负的临床期生物技术公司而言，高管减持信号容易放大市场对公司前景的疑虑。Spyre Therapeutics是一家专注于炎症性肠病的生物技术公司，产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体，当前市净率约12.39倍，总市值约83亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134617087","title":"异动解读｜SPYRE THERAPEUTICS盘前下跌10.83%，报86.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134617087","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134617087?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:02","pubTimestamp":1782288144,"startTime":"0","endTime":"0","summary":"6月24日，SPYRE THERAPEUTICS盘前下跌10.83%，报86.54美元/股，成交额1.75万美元。SPYRE THERAPEUTICS所在的生物科技行业中，个股表现分化，艾伯维公司涨0.63%，Apogee Therapeutics涨1.44%，吉利德科学跌0.14%，安进跌0.42%，再生元制药公司涨0%。其产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133633236","title":"异动解读｜SPYRE THERAPEUTICS夜盘下跌7.91%，报89.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133633236","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133633236?lang=zh_cn&edition=full","pubTime":"2026-06-24 08:23","pubTimestamp":1782260607,"startTime":"0","endTime":"0","summary":"6月24日，SPYRE THERAPEUTICS夜盘下跌7.91%，报89.37美元/股，成交额179.0美元。SPYRE THERAPEUTICS所在的生物科技行业中，个股表现平淡，艾伯维公司涨0%，Apogee Therapeutics涨0%，吉利德科学跌0.94%，安进涨0%，再生元制药公司涨0%。其产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121301590","title":"异动解读｜SPYRE THERAPEUTICS盘后上涨8.19%，报105.0美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1121301590","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121301590?lang=zh_cn&edition=full","pubTime":"2026-06-24 04:41","pubTimestamp":1782247295,"startTime":"0","endTime":"0","summary":"6月23日，SPYRE THERAPEUTICS盘后上涨8.19%，报105.0美元/股，成交额411.19万美元。SPYRE THERAPEUTICS所在的生物科技行业中，个股表现分化，艾伯维公司跌0.22%，Apogee Therapeutics跌0.14%，吉利德科学涨0.32%，再生元制药公司跌0.01%，安进跌0.58%。其产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132100150","title":"Spyre Therapeutics：二十名受试者出现治疗引发不良事件；两例严重，均与药物无关","url":"https://stock-news.laohu8.com/highlight/detail?id=1132100150","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132100150?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:03","pubTimestamp":1781525007,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics公布了一项临床试验的更新数据，显示有二十名受试者出现了治疗引发的不良事件。其中，两例被评估为严重级别，但经过分析，这些严重事件均被判定与试验药物本身无关。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107639416","title":"SPYRE THERAPEUTICS：Spy002在第12周实现33%临床缓解与42%内镜改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1107639416","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107639416?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:02","pubTimestamp":1781524958,"startTime":"0","endTime":"0","summary":"SPYRE THERAPEUTICS公司宣布，其候选药物Spy002在治疗第12周时取得了令人鼓舞的临床数据。\n结果显示，接受治疗的患者中有33%达到了临床缓解的标准。同时，内镜检查评估显示，42%的患者实现了内镜下病情的显著改善。\n这些中期数据为该药物的后续开发提供了积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178318875","title":"Spyre公布其潜在同类最佳药物Spy002（抗TL1A）在Skyline试验中治疗中重度溃疡性结肠炎患者的A部分诱导结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1178318875","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178318875?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:01","pubTimestamp":1781524915,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics公司宣布，其候选药物Spy002（一种抗TL1A疗法）在针对中重度溃疡性结肠炎患者的Skyline试验中，取得了A部分的诱导期结果。数据显示，该药物展现出成为同类最佳疗法的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196395365","title":"Spyre Therapeutics宣布Skyway篮子试验完成患者入组，评估Spy072（抗TL1A）治疗RA、PsA及AxSpa","url":"https://stock-news.laohu8.com/highlight/detail?id=1196395365","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196395365?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:08","pubTimestamp":1780488531,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc (SPYRE THERAPEUTICS INC) 已宣布，其针对Spy072（一种抗TL1A疗法）的Skyway篮子试验患者入组工作现已完成。该试验旨在评估该疗法对类风湿关节炎（RA）、银屑病关节炎（PsA）以及中轴型脊柱关节炎（AxSpa）患者的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146674317","title":"Spyre Therapeutics重申预期：类风湿关节炎试验数据将于2026年第三季度揭晓，银屑病关节炎与中轴型脊柱关节炎数据预计第四季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1146674317","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146674317?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:06","pubTimestamp":1780488378,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics公司再次确认其关键临床试验的预期数据公布时间线。针对类风湿关节炎（Ra）的研究数据，预计将在2026年第三季度获得并公布。此外，关于银屑病关节炎（Psa）以及中轴型脊柱关节炎（Axspa）的试验数据，公司则预计将在2026年第四季度陆续揭晓。\n这一时间表的重申，为关注该公司研发管线的投资者提供了明确的关键节点。不同适应症的数据分阶段出炉，或将影响市场对公司未来前景的评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162858091","title":"Spyre Therapeutics：Skyway与Skyline试验齐头并进，计划中的“2026年六项”二期数据读出已就绪并按计划推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1162858091","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162858091?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:06","pubTimestamp":1780488377,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics宣布，其Skyway与Skyline临床试验项目进展顺利，原定于2026年完成的六项二期研究数据读出已具备条件，并正按既定时间表稳步推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.spyre.com","stockEarnings":[{"period":"1week","weight":-0.0329},{"period":"1month","weight":-0.1733},{"period":"3month","weight":-0.0056},{"period":"6month","weight":0.8637},{"period":"1year","weight":4.5037},{"period":"ytd","weight":1.6914}],"compareEarnings":[{"period":"1week","weight":0.0182},{"period":"1month","weight":0.0057},{"period":"3month","weight":0.0456},{"period":"6month","weight":0.2109},{"period":"1year","weight":0.1577},{"period":"ytd","weight":0.126}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Spyre Therapeutics, Inc.于2013年12月16日从特拉华州有限责任公司转换而来。该公司是一家生物技术公司，旨在通过结合同类最佳的抗体工程、合理的治疗组合以及用于患者选择的精准医疗方法，创造下一代炎症性肠病（IBD）产品。Spyre的产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.035303},{"month":2,"riseRate":0.5,"avgChangeRate":0.028912},{"month":3,"riseRate":0.5,"avgChangeRate":0.022238},{"month":4,"riseRate":0.2,"avgChangeRate":-0.009955},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.054533},{"month":6,"riseRate":0.454545,"avgChangeRate":0.127238},{"month":7,"riseRate":0.454545,"avgChangeRate":0.007753},{"month":8,"riseRate":0.727273,"avgChangeRate":0.090721},{"month":9,"riseRate":0.545455,"avgChangeRate":0.013832},{"month":10,"riseRate":0.4,"avgChangeRate":0.109394},{"month":11,"riseRate":0.4,"avgChangeRate":0.005048},{"month":12,"riseRate":0.4,"avgChangeRate":-0.019416}],"exchange":"NASDAQ","name":"SPYRE THERAPEUTICS INC","nameEN":"SPYRE THERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SPYRE THERAPEUTICS INC(SYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供SPYRE THERAPEUTICS INC(SYRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"SPYRE THERAPEUTICS INC,SYRE,SPYRE THERAPEUTICS INC股票,SPYRE THERAPEUTICS INC股票老虎,SPYRE THERAPEUTICS INC股票老虎国际,SPYRE THERAPEUTICS INC行情,SPYRE THERAPEUTICS INC股票行情,SPYRE THERAPEUTICS INC股价,SPYRE THERAPEUTICS INC股市,SPYRE THERAPEUTICS INC股票价格,SPYRE THERAPEUTICS INC股票交易,SPYRE THERAPEUTICS INC股票购买,SPYRE THERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SPYRE THERAPEUTICS INC(SYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供SPYRE THERAPEUTICS INC(SYRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}